Bifeprunox: Development discontinued

Solvay and H. Lundbeck A/S (CSE:LUN, Copenhagen, Denmark) will discontinue development of bifeprunox after an interim analysis of efficacy data from Phase III trials to treat schizophrenia indicated ...